EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Experiences of People Who Discontinue Long‐Acting Injectable Buprenorphine Treatment Recently Released From Prison in New South Wales, Australia

Lucy J D Peck iD, Bethany White iD, Maja Moensted iD, Michael F Doyle iD, Elizabeth McEntyre, Antoni Pazeski, Samuel Lawson, Jillian Roberts, Paul S Haber, Nicholas Lintzeris iD, Adrian J Dunlop iD, Lisa Maher

Drug and Alcohol Review · 2026

DOI: 10.1111/dar.70096 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug and Alcohol Review, 2026. Verfasst von Lucy J D Peck und 11 weiteren Autor:innen. Beteiligte Einrichtung: Edith Collins Translational Research Centre, Drug Health Services, Sydney Local Health District, Sydney, Australia. Hauptthemen laut MEDLINE: Buprenorphine, Opioid-Related Disorders, Opiate Substitution Treatment, Prisoners. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NSW Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Among other benefits, opioid agonist treatment (OAT; methadone and buprenorphine) is protective against overdose for people with opioid use disorder following release from custody. Long‐acting injectable buprenorphine (LAIB) is safe with an apparent low risk of diversion relative to other OAT formulations in correctional settings and may become a preferred OAT formulation in this setting. Factors that influence retention in LAIB post‐release are unknown.

Method

People receiving LAIB in nine New South Wales prisons were consented to participate in a survey designed to explore treatment experiences post‐release. Participants who reported ceasing LAIB within 12 weeks of release were invited to complete an in‐depth interview using a semi‐structured guide via phone or secure videoconference in the community, or in custody if reincarcerated. Interviews were transcribed verbatim, and data analysed using iterative categorisation and thematic analysis.

Results

A total of 31 participants who ceased LAIB within 12 weeks following release from custody were interviewed. Mean age was 34 years (SD 9), 24 were male and 16 identified as Aboriginal People. Key themes regarding treatment cessation were misinformation and lack of treatment education, limited transition supports for housing, mental health and illicit substance use, and changing treatment benefits between the custody and community contexts including illicit substance preferences and side effects. Discussion and Conclusions Numerous personal experiences and psychosocial factors impacted participant motivations and capacity to continue LAIB post‐release. Understanding and addressing these factors is necessary to support treatment retention and increase community‐based program acceptability and continuation in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BuprenorphineOpioid-Related DisordersOpiate Substitution TreatmentPrisonersNarcotic AntagonistsHumansMaleNew South WalesAdultFemalePrisonsDelayed-Action PreparationsMiddle Aged

Stichwörter der Autor:innen

custodylong‐acting injectable buprenorphinepost‐releasequalitativeretention

Substanzen

BuprenorphineDelayed-Action PreparationsNarcotic Antagonists

Autor:innen und Institutionen

  • Edith Collins Translational Research Centre, Drug Health Services, Sydney Local Health District, Sydney, Australia.
  • Specialty of Addiction Medicine, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.
  • Drug & Alcohol Clinical Research & Improvement Network, Sydney, Australia.
  • Mura Leadership Program Fellow, Speciality of Addiction Medicine, The University of Sydney, Sydney, Australia.
  • Worimi Guringai and Wonnarua Researcher, Australia.
  • Drug & Alcohol Clinical Services, Hunter New England Local Health District, Newcastle, Australia.

ORCID-Profile: Lucy J D Peck, Bethany White, Maja Moensted, Michael F Doyle, Nicholas Lintzeris, Adrian J Dunlop

Förderung

  • NSW Health

Zitieren

APA

Peck, L. J. D., White, B., Moensted, M., Doyle, M. F., McEntyre, E., Pazeski, A., Lawson, S., Roberts, J., Haber, P. S., Lintzeris, N., Dunlop, A. J., & Maher, L. (2026). Experiences of People Who Discontinue Long‐Acting Injectable Buprenorphine Treatment Recently Released From Prison in New South Wales, Australia. Drug and Alcohol Review. https://doi.org/10.1111/dar.70096

Vancouver

Peck LJD, White B, Moensted M, Doyle MF, McEntyre E, Pazeski A, et al. Experiences of People Who Discontinue Long‐Acting Injectable Buprenorphine Treatment Recently Released From Prison in New South Wales, Australia. Drug and Alcohol Review. 2026. doi:10.1111/dar.70096

BibTeX
@article{Peck2026,
  author = {Peck, Lucy J D and White, Bethany and Moensted, Maja and Doyle, Michael F and McEntyre, Elizabeth and Pazeski, Antoni and Lawson, Samuel and Roberts, Jillian and Haber, Paul S and Lintzeris, Nicholas and Dunlop, Adrian J and Maher, Lisa},
  title = {Experiences of People Who Discontinue Long‐Acting Injectable Buprenorphine Treatment Recently Released From Prison in New South Wales, Australia},
  journal = {Drug and Alcohol Review},
  year = {2026},
  doi = {10.1111/dar.70096}
}
Kostenlos starten →